Product Information
LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.0293 per EA under NDC 76282044601. Its NADAC has been published 365 times since Oct 9, 2019.
FDA first approved this application on May 23, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB
Lisinopril and Hydrochlorothiazide TabletsStrength
12.5; 10 mg/1; mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282044601
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; LISINOPRILApproval Type
Generic (ANDA)
FDA Application
ANDA204058FDA Approved
5/23/2017
TE Code
AB
On Market Since
5/1/2019
Pharmacological Classes
Price Statistics
The NADAC for LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has been published 365 times since Oct 9, 2019, and over the history we have for it it has declined 21.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0293 per EA |
|---|---|
| All-time high | $0.0407 (Aug 11, 2021) |
| All-time low | $0.0241 (Nov 20, 2024) |
| 52-week high | $0.0307 |
| 52-week low | $0.0284 |
| Median price | $0.0335 |
| Average price | $0.0336 |
| Largest weekly change | -25.4% (Nov 20, 2024) |
| Weeks tracked | 365 |
| Tracking since | Oct 9, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lisinopril and Hydrochlorothiazide Tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB, manufactured by Exelan Pharmaceuticals Inc., is $0.0293 per EA (NDC 76282044601), effective Sep 30, 2026.
How has the price of LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has declined 21.0%. It has been tracked across 365 weekly CMS publications since Oct 9, 2019.
What are the highest and lowest recorded NADAC prices for LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
Since Oct 9, 2019, the NADAC for LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has ranged from a low of $0.0241 (Nov 20, 2024) to a high of $0.0407 (Aug 11, 2021), with a median of $0.0335 per EA.
Are there cheaper alternatives to LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
LISINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB (NDC 76282044601) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.